mHealth to help pregnant and postpartum women in recovery for opioid use disorder

移动医疗帮助孕妇和产后妇女恢复阿片类药物使用障碍

• 批准号: 10268160
• 负责人: Patricia A Cavazos-Rehg
• 金额: $ 23.63万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-30 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10268160
• 关键词: Adult; African American; Area; Attitude; Behavior; Caring; Characteristics; Clinic; Clinical; Control Groups; Data; Drug Prescriptions; Education; Effectiveness; Feedback; Focus Groups; Grant; Health Technology; High Risk Woman; Hospitals; Individual; Infant Care; International; Intervention; Interview; Intuition; Life; Measures; Methods; Minority Groups; Missouri; Names; Opioid; Outcome; Participant; Perinatal; Persons; Physicians; Postpartum Women; Poverty; Pregnancy; Pregnant Women; Prevalence; Provider; Public Health; Randomized; Randomized Controlled Trials; Recovery; Reporting; Research Project Grants; Signal Transduction; Site; Standardization; Suggestion; Testing; Time; United States Substance Abuse and Mental Health Services Administration; Universities; Visit; Vulnerable Populations; Washington; Woman; Work; acceptability and feasibility; base; clinical care; control trial; design; digital treatment; empowerment; feasibility testing; follow up assessment; follower of religion Jewish; high risk; high school; improved; mHealth; medical schools; medication-assisted treatment; mobile application; new technology; opioid abuse; opioid epidemic; opioid mortality; opioid use disorder; racial and ethnic; recruit; response; satisfaction; sobriety; standard of care; theories; tool; treatment adherence; treatment as usual; treatment planning; treatment risk; trend; usability; Adult; African American; Area; Attitude; Behavior; Caring; Characteristics; Clinic; Clinical; Control Groups; Data; Drug Prescriptions; Education; Effectiveness; Feedback; Focus Groups; Grant; Health Technology; High Risk Woman; Hospitals; Individual; Infant Care; International; Intervention; Interview; Intuition; Life; Measures; Methods; Minority Groups; Missouri; Names; Opioid; Outcome; Participant; Perinatal; Persons; Physicians; Postpartum Women; Poverty; Pregnancy; Pregnant Women; Prevalence; Provider; Public Health; Randomized; Randomized Controlled Trials; Recovery; Reporting; Research Project Grants; Signal Transduction; Site; Standardization; Suggestion; Testing; Time; United States Substance Abuse and Mental Health Services Administration; Universities; Visit; Vulnerable Populations; Washington; Woman; Work; acceptability and feasibility; base; clinical care; control trial; design; digital treatment; empowerment; feasibility testing; follow up assessment; follower of religion Jewish; high risk; high school; improved; mHealth; medical schools; medication-assisted treatment; mobile application; new technology; opioid abuse; opioid epidemic; opioid mortality; opioid use disorder; racial and ethnic; recruit; response; satisfaction; sobriety; standard of care; theories; tool; treatment adherence; treatment as usual; treatment planning; treatment risk; trend; usability

The opioid epidemic has resulted in widespread detrimental consequences among vulnerable populations in Missouri, especially among pregnant and postpartum women (PPW) with opioid use disorder (OUD). Perinatal use of medication-assisted treatment (MAT) within a comprehensive treatment plan is the current standard of care, however PPW struggling with OUD may underestimate or misjudge its benefits. At the same time, emerging findings signal that mobile health (mHealth) technologies have the potential to support healthier behaviors among individuals with OUD. In this project, we will test the utility of a theoretically-based digital therapeutics tool (uMAT-R) to encourage MAT adherence and treatment retention while considering the unique needs of PPW. In Aim #1, we will conduct four focus groups with PPW with OUD (target users) on the intervention components of uMAT-R, gathering feedback on theory-driven components that are candidates for inclusion in the tool and eliciting suggestions for additional intervention components. In Aim #2, the tool will be beta-tested for technical/navigational issues among 20 participants. In Aim #3, we will conduct a pilot randomized controlled trial (RCT) among adult PPW with OUD (n=60). This RCT is designed to test the feasibility, acceptability, and preliminary efficacy of uMAT-R (n=40) versus a control group (n=20 who receive treatment-as-usual) regarding participants’ treatment adherence, sobriety, and improved MAT attitudes, norms, and perceived control. Recruitment for all Aims will occur at a clinic in St. Louis, Missouri that provides perinatal medication-assisted treatment (MAT) and high-risk maternity care to PPW struggling with OUD. Clinically meaningful effect size and attrition estimates will aid in the planning of a larger RCT in which we will test uMAT-R on a larger scale and expand our recruitment to other clinics across Missouri and other states. This novel technology could be an invaluable tool to assist physicians in the treatment of OUD among PPW.

阿片类药物流行导致脆弱的宽度有害后果 密苏里州的人口，特别是在怀孕和产后妇女（PPW）中 使用障碍（OUD）。围产期使用药物辅助治疗（MAT） 全面的治疗计划是当前的护理标准，但是PPW与 Oud可能会低估或错过其利益。同时，新兴发现信号 该移动健康（MHealth）技术有可能支持更健康的行为 在有Oud的个人中。在这个项目中，我们将测试基于理论的实用性 数字疗法工具（UMAT-R）鼓励MAT依从性和保留率 考虑PPW的独特需求。在AIM＃1中，我们将与PPW进行四个焦点小组 使用OUD（目标用户）在UMAT-R的干预组件上，收集反馈 理论驱动的组件是候选者，并引起建议 用于其他干预组件。在AIM＃2中，该工具将经过beta测试 20名参与者之间的技术/导航问题。在AIM＃3中，我们将进行飞行员 OUD成人PPW中的随机对照试验（RCT）（n = 60）。此RCT设计为 测试UMAT-R（n = 40）的可行性，可接受性和初步效率与对照 关于参与者的治疗依从性的组（n = 20 清醒和改善的垫子参加，规范和感知的控制。招募所有目标 将在密苏里州圣路易斯的一家诊所发生，该诊所提供围产期药物辅助治疗 （MAT）和高风险的成熟护理与PPW与Oud斗争。临床上有意义的效果 尺寸和属性估计值将有助于规划较大的RCT，我们将测试UMAT-R 大规模的规模并将我们的招聘扩展到密苏里州和其他州的其他诊所。 这项新型技术可能是协助医师治疗Oud的宝贵工具 在PPW中。